カテゴリ： GlobalData, アメリカ, 企業調査

Akcea Therapeutics Inc (AKCA)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Akcea Therapeutics Inc (AKCA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C8132
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：61
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Akcea Therapeutics Inc (Akcea Therapeutics), a subsidiary of Ionis Pharmaceuticals Inc, is a developer and commercializer of drugs to treat patients with cardiometabolic diseases caused by lipid disorders. The company’s drugs are designed based on advanced antisense technology. Its pipeline product includes volanesorsen, an antisense drug that reduces ApoC-III protein production and lowers triglycerides in patients with dyslipidemia. Akcea Therapeutics also offer products for recurring cardiovascular disease with high lipoprotein, calcific aortic stenosis with high lipoprotein, severe high triglycerides, mixed dyslipidemias and high triglycerides with type 2 diabetes, among others. It also conducts clinical trials for the development of its products. Akcea Therapeutics is headquartered in Cambridge, Massachusetts, the US.

Akcea Therapeutics Inc (AKCA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Novartis Enters into Option Agreement with Ionis Pharma and Akcea Therapeutics 11
Licensing Agreements 13
PTC Therapeutics Enters into Licesing Agreement with Akcea Therapeutics 13
Akcea Therapeutics Enters into Licensing Agreement with Ionis Pharma 14
Akcea Therapeutics Inc – Key Employees 17
Akcea Therapeutics Inc – Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Strategy And Business Planning 19
Sep 06, 2017: Akcea Therapeutics Establishes Canadian Subsidiary 19
Financial Announcements 20
Aug 06, 2018: Akcea reports financial results and highlights for second quarter 2018 20
May 03, 2018: Akcea Reports Financial Results and Highlights for First Quarter 2018 22
Feb 26, 2018: Akcea Reports Financial Results and Highlights for Fourth Quarter and Year End 2017 24
Nov 06, 2017: Akcea Reports Financial Results and Highlights for Third Quarter 2017 26
Aug 08, 2017: Akcea Reports Financial Results and Highlights for Second Quarter 2017 28
Corporate Communications 30
Oct 08, 2018: Akcea announces changes to Board of Directors 30
Jun 05, 2018: Akcea Therapeutics Names Dr. Richard Moscicki As Board Director 31
Apr 17, 2018: Sarah Boyce Joins Akcea Therapeutics As President And Member Of Board Of Directors 32
Sep 05, 2017: Akcea Expands Leadership Team in Preparation for First Commercial Launch 33
May 09, 2017: Akcea Therapeutics Announces Appointment of Edward Fitzgerald to Board of Directors 35
Mar 28, 2017: Akcea Therapeutics Announces Three Additions to Board of Directors 36
Product News 37
10/16/2017: Akcea Presents Data Demonstrating Significant Burden of Illness in Familial Chylomicronemia Syndrome 37
07/11/2017: New Data Reveal Hidden Burden of Familial Chylomicronaemia Syndrome 38
05/02/2018: Akcea Announces Expansion of Global Early Access Program to Provide Volanesorsen to People Living with FCS 39
03/21/2018: MHRA Grants UK Patients Early Access to Akcea Therapeutics’ Volanesorsen for Familial Chylomicronaemia Syndrome (FCS) 40
03/12/2018: Positive Phase 1/2 Results of AKCEA-APOCIII-LRx Presented at American College of Cardiology Annual Scientific Session & Expo 41
02/28/2018: Akcea Therapeutics Recognizes Rare Disease Day by Spotlighting Several Historic “Firsts” for People Living with Familial Chylomicronemia Syndrome 43
02/15/2018: Akcea Announces FDA Advisory Committee Meeting to Review Volanesorsen as a Treatment for Familial Chylomicronemia Syndrome 44
Product Approvals 45
Nov 15, 2017: Akcea and Ionis Announce Acceptance of Marketing Applications in U.S., EU and Canada for Volanesorsen for the Treatment of FCS 45
Oct 10, 2017: Akcea Therapeutics’ Volanesorsen Receives Promising Innovative Medicine (PIM) Status for the Treatment of Familial Chylomicronaemia Syndrome (FCS) 46
Sep 12, 2017: Akcea Announces Filing of New Drug Submission for Volanesorsen to Health Canada 47
Aug 31, 2017: Akcea and Ionis Announce Submission of New Drug Application for Volanesorsen to the U.S. FDA 49
Jul 27, 2017: Akcea and Ionis Announce Submission of Marketing Authorization Application for Volanesorsen to the European Medicines Agency 51
Clinical Trials 52
Apr 26, 2018: Akcea Therapeutics Announces Presentations on Volanesorsen and FCS at the National Lipid Association Scientific Sessions 52
Jan 05, 2018: Akcea Initiates Phase 2b Study of AKCEA-APOCIII-LRx in Patients with Hypertriglyceridemia and Established Cardiovascular Disease 53
Oct 31, 2017: Akcea and Ionis Report Positive Phase 1/2a Data with AKCEA-APOCIII-LRx 55
Aug 08, 2017: Akcea Provides Update on AKCEA-APOCIII-LRx 56
Mar 30, 2017: Akcea Initiates Phase 2 Study of AKCEA-APO(a)-L Rx in Patients with High Lp(a) and Cardiovascular Disease 57
Mar 06, 2017: Akcea and Ionis Announce Positive Results from Pivotal Study of Volanesorsen in Patients with Familial Chylomicronemia Syndrome 58
Other Significant Developments 60
Jun 12, 2018: Akcea and Ambry Genetics to Launch hATTR Compass, a Genetic Testing Program for People with Suspected Hereditary ATTR Amyloidosis 60
Appendix 61
Methodology 61
About GlobalData 61
Contact Us 61
Disclaimer 61

List of Tables
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Akcea Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Novartis Enters into Option Agreement with Ionis Pharma and Akcea Therapeutics 11
PTC Therapeutics Enters into Licesing Agreement with Akcea Therapeutics 13
Akcea Therapeutics Enters into Licensing Agreement with Ionis Pharma 14
Akcea Therapeutics Inc, Key Competitors 16
Akcea Therapeutics Inc, Key Employees 17

List of Figures
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Akcea Therapeutics Inc (AKCA)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Eolus Vind AB (EOLU B)：企業の財務・戦略的SWOT分析
    Summary Eolus Vind AB (Eolus Vind) is a wind farm developer that offers construction, development, and operation of green field projects and wind power plants. The company provides services such as consultancy services, administration, financing, development, and management of wind farms. It also of …
  • CH. Karnchang Public Company Limited (CK)：企業の財務・戦略的SWOT分析
    CH. Karnchang Public Company Limited (CK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Assertio Therapeutics Inc (DEPO)：製薬・医療：M&Aディール及び事業提携情報
    Summary Assertio Therapeutics Inc (Assertio), formerly Depomed Inc, is a specialty pharmaceutical company that develops and commercializes drugs for the treatment of pain and other diseases of the central nervous system. Its product portfolio comprises drugs for the treatment of postherpetic neuralg …
  • Ergomed Plc (ERGO)：企業の財務・戦略的SWOT分析
    Summary Ergomed Plc (Ergomed), formerly Ergomed Clinical Research Ltd, is a drug development and clinical research services provider. The company provides various services such as regulatory and quality management, biostatistics, study management, clinical data management, medical writing, and other …
  • HearMeOut Ltd (HMO)：企業の財務・戦略的SWOT分析
    HearMeOut Ltd (HMO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • AnGes Inc (4563)：企業の財務・戦略的SWOT分析
    AnGes Inc (4563) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Assam Company India Ltd (ASSAMCO)：企業の財務・戦略的SWOT分析
    Assam Company India Ltd (ASSAMCO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Ryoden Trading Co Ltd：企業の戦略・SWOT・財務情報
    Ryoden Trading Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Ryoden Trading Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Zehnder Group AG (ZEHN)：企業の財務・戦略的SWOT分析
    Zehnder Group AG (ZEHN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Swiber Holdings Ltd (AK3)-石油・ガス分野：企業M&A・提携分析
    Summary Swiber Holdings Limited (Swiber) is a provider of integrated offshore construction and support services to the oil and gas industry. The company offers offshore engineering, procurement, installation and construction (EPIC) and marine support services. Its offshore construction services incl …
  • Phatra Leasing Public Company Limited (PL)：企業の財務・戦略的SWOT分析
    Phatra Leasing Public Company Limited (PL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengt …
  • Mega Financial Holding Co., Ltd.：戦略・SWOT・企業財務分析
    Mega Financial Holding Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Mega Financial Holding Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Turcas Petrol AS (TRCAS)：企業の財務・戦略的SWOT分析
    Summary Turcas Petrol AS (Turcas) is an oil and gas company that distributes and markets lubricants and fuel products. The company operates in the fields of oil and energy, renewable energy, power investments, natural gas projects, fuel retail and lubricants distribution, and power generation and tr …
  • FXI, Inc.：企業の戦略的SWOT分析
    FXI, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • TransGlobe Energy Corp (TGL)：企業の財務・戦略的SWOT分析
    Summary TransGlobe Energy Corp (TransGlobe Energy) is an oil and gas company that explores, develops and produces crude oil and natural gas. The company develops oil and natural gas properties in the Arab Republic of Egypt and the Republic of Yemen. It holds interests in various production sharing c …
  • Presence Health：企業の戦略的SWOT分析
    Presence Health - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Korea Midland Power Co Ltd-エネルギー分野：企業M&A・提携分析
    Summary Korea Midland Power Co., Ltd. (Komipo), a subsidiary of Korea Electric Power Corporation, is an electric utility which generates electricity; operates power plants; and provides various energy services. The company produces electricity from bituminous coal, anthracite coal, liquefied natural …
  • Basin Electric Power Cooperative：企業の戦略・SWOT・財務分析
    Basin Electric Power Cooperative - Strategy, SWOT and Corporate Finance Report Summary Basin Electric Power Cooperative - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • SalvaRx Group plc (SALV)：企業の財務・戦略的SWOT分析
    Summary SalvaRx Group Plc (SalvaRx), formerly 3Legs Resources plc, is a drug development company that offers acquiring and operating drug development programmes in immuno-oncology. The company offers immune oncology. It invests in novel cancer immune-therapies. SalvaRx provides development of a pipe …
  • Dart Group PLC：企業の戦略・SWOT・財務情報
    Dart Group PLC - Strategy, SWOT and Corporate Finance Report Summary Dart Group PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆